Haemonetics Corporation (HAE)
Automate Your Wheel Strategy on HAE
With Tiblio's Option Bot, you can configure your own wheel strategy including HAE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HAE
- Rev/Share 27.663
- Book/Share 19.3443
- PB 3.5147
- Debt/Equity 1.2871
- CurrentRatio 1.6173
- ROIC 0.0806
- MktCap 3266035630.0
- FreeCF/Share 2.8957
- PFCF 22.9281
- PE 19.9466
- Debt/Assets 0.4997
- DivYield 0
- ROE 0.1841
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HAE | BofA Securities | Neutral | Underperform | $95 | $68 | Feb. 7, 2025 |
| Initiation | HAE | JP Morgan | -- | Overweight | -- | $116 | Dec. 6, 2024 |
| Initiation | HAE | CL King | -- | Buy | -- | $116 | Sept. 13, 2024 |
| Initiation | HAE | BofA Securities | -- | Neutral | -- | $85 | Sept. 11, 2024 |
| Initiation | HAE | BTIG Research | -- | Buy | -- | $112 | Sept. 10, 2024 |
News
HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Haemonetics' fourth-quarter fiscal 2025 results reflect the positive impact of its long-term plan, with meaningful earnings growth and margin expansion.
Read More
Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral
Financial release accessible online BOSTON , May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.
Read More
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
Read More
Is it Apt to Retain HAE Stock in Your Portfolio for Now?
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Strong prospects for the Hospital Business and the robust NexSys PCS system bode well for Haemonetics.
Read More
Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
BOSTON , Feb. 24, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025 at 2:50 p.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://wsw.com/webcast/rj131/hae/1437678.
Read More
About Haemonetics Corporation (HAE)
- IPO Date 1991-05-10
- Website https://www.haemonetics.com
- Industry Medical - Instruments & Supplies
- CEO Mr. Christopher A. Simon
- Employees 3657